Search research articles
Contact Us
Filters
Showing results (71-80 of 95) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
M A Villalona-Calero, S D Baker, L Hammond, et al.
Cancer Chemotherapy and Pharmacology
|
September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
D A Rinaldi, J G Kuhn, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
E K Rowinsky, L Smith, Y M Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
L A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
E K Rowinsky, T R Johnson, C E Geyer, et al.
Anti-Cancer Drugs
|
July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Anna Capasso, Todd M Pitts, Peter J Klauck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
M A Villalona-Calero, G R Weiss, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I study of recombinant human CD40 ligand in cancer patients
R H Vonderheide, J P Dutcher, J E Anderson, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 95) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
M A Villalona-Calero, S D Baker, L Hammond, et al.
Cancer Chemotherapy and Pharmacology
|
September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
D A Rinaldi, J G Kuhn, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
E K Rowinsky, L Smith, Y M Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
L A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
E K Rowinsky, T R Johnson, C E Geyer, et al.
Anti-Cancer Drugs
|
July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Anna Capasso, Todd M Pitts, Peter J Klauck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
M A Villalona-Calero, G R Weiss, H A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I study of recombinant human CD40 ligand in cancer patients
R H Vonderheide, J P Dutcher, J E Anderson, et al.
Page
of 10